Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
4932417H 02Rik | |
AK029341 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832440O09 product:Hypothetical ARM repeat structure containing protein, full insert sequence. [AK029341] |
KLA | .90 |
.86 |
.81 |
.84 |
.93 |
.84 |
.93 |
| ATP | 1.00 |
1.06 |
1.02 |
.88 |
.93 |
.76 |
1.06 |
| KLA/ATP | .90 |
.86 |
.88 |
.79 |
.83 |
.80 |
.98 |
|
4932417H 02Rik | |
NM_028898 |
RIKEN cDNA 4932417H02 gene (4932417H02Rik), mRNA [NM_028898] |
KLA | .76 |
.72 |
.83 |
.63 |
.61 |
.68 |
.75 |
| ATP | .99 |
.95 |
.79 |
.76 |
.66 |
.62 |
1.47 |
| KLA/ATP | .78 |
.71 |
.56 |
.50 |
.39 |
.48 |
.89 |
|
AK045366
| |
AK045366 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230107A03 product:unclassifiable, full insert sequence [AK045366] |
KLA | .88 |
.80 |
.79 |
.86 |
.89 |
.97 |
1.07 |
| ATP | 1.21 |
1.67 |
2.40 |
3.50 |
2.58 |
1.29 |
1.12 |
| KLA/ATP | .97 |
.98 |
1.30 |
1.76 |
1.26 |
1.15 |
1.06 |
|
Acaca | |
NM_133360 |
acetyl-Coenzyme A carboxylase alpha (Acaca), mRNA [NM_133360] |
KLA | .99 |
.94 |
.95 |
.93 |
.95 |
1.00 |
1.00 |
| ATP | .98 |
.97 |
.96 |
.93 |
.92 |
.96 |
.99 |
| KLA/ATP | 1.01 |
.96 |
.99 |
.92 |
.93 |
.94 |
.91 |
|
Acacb | |
NM_133904 |
acetyl-Coenzyme A carboxylase beta (Acacb), mRNA [NM_133904] |
KLA | 1.01 |
.93 |
1.00 |
.99 |
.95 |
1.03 |
.92 |
| ATP | .96 |
1.04 |
1.05 |
.98 |
1.04 |
1.11 |
1.05 |
| KLA/ATP | .90 |
1.01 |
1.05 |
1.03 |
.97 |
.96 |
1.08 |
|
Akt1 | |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 | |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 | |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Araf | |
NM_009703 |
v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] |
KLA | .87 |
.80 |
.89 |
.93 |
1.10 |
1.19 |
1.16 |
| ATP | 1.09 |
1.11 |
1.19 |
1.18 |
.78 |
.53 |
1.18 |
| KLA/ATP | 1.00 |
.95 |
.99 |
.93 |
.63 |
.55 |
1.27 |
|
Bad | |
AK029400 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] |
KLA | 1.15 |
1.22 |
1.26 |
1.31 |
1.40 |
1.67 |
1.59 |
| ATP | .95 |
1.06 |
1.12 |
1.06 |
.78 |
.89 |
1.27 |
| KLA/ATP | 1.25 |
1.39 |
1.33 |
1.29 |
1.11 |
.91 |
1.38 |
|
Braf | |
NM_139294 |
Braf transforming gene (Braf), mRNA [NM_139294] |
KLA | 1.52 |
1.57 |
1.55 |
1.33 |
1.83 |
1.52 |
1.60 |
| ATP | 1.08 |
1.17 |
1.02 |
1.37 |
.95 |
1.15 |
.95 |
| KLA/ATP | 1.64 |
1.69 |
1.39 |
1.51 |
1.04 |
1.31 |
1.26 |
|
Calm1 | |
NM_009790 |
calmodulin 1 (Calm1), mRNA [NM_009790] |
KLA | 1.20 |
1.26 |
1.30 |
1.06 |
1.16 |
1.09 |
1.18 |
| ATP | 1.07 |
1.20 |
1.00 |
1.29 |
.99 |
.64 |
.58 |
| KLA/ATP | 1.31 |
1.31 |
.93 |
1.31 |
.97 |
.83 |
.59 |
|
Calm2 | |
NM_007589 |
calmodulin 2 (Calm2), mRNA [NM_007589] |
KLA | .79 |
.81 |
.71 |
.67 |
.54 |
.45 |
.64 |
| ATP | .99 |
1.03 |
1.04 |
.93 |
.82 |
.52 |
.76 |
| KLA/ATP | .76 |
.78 |
.76 |
.77 |
.73 |
.47 |
.42 |
|
Calm3 | |
NM_007590 |
calmodulin 3 (Calm3), mRNA [NM_007590] |
KLA | .95 |
.96 |
.93 |
1.03 |
1.05 |
1.08 |
1.00 |
| ATP | .93 |
.96 |
.99 |
.97 |
.93 |
.84 |
.72 |
| KLA/ATP | .89 |
.93 |
.90 |
.91 |
1.02 |
.98 |
.70 |
|
Calm4 | |
NM_020036 |
calmodulin 4 (Calm4), mRNA [NM_020036] |
KLA | 1.02 |
.96 |
1.05 |
1.00 |
.99 |
1.00 |
1.01 |
| ATP | 1.10 |
1.05 |
1.03 |
1.01 |
.94 |
.98 |
.98 |
| KLA/ATP | .99 |
1.12 |
1.01 |
1.03 |
.98 |
1.07 |
1.02 |
|
Calm5 | |
NM_001008706 |
calmodulin 5 (Calm5), mRNA [NM_001008706] |
KLA | 1.02 |
1.11 |
.99 |
.98 |
1.07 |
1.01 |
1.09 |
| ATP | 1.07 |
1.05 |
1.04 |
1.04 |
1.01 |
1.04 |
.99 |
| KLA/ATP | 1.00 |
1.00 |
.97 |
1.07 |
1.00 |
1.07 |
.98 |
|
Calml3 | |
NM_027416 |
calmodulin-like 3 (Calml3), mRNA [NM_027416] |
KLA | 1.01 |
.95 |
1.05 |
.91 |
1.01 |
.98 |
.89 |
| ATP | .91 |
1.05 |
1.04 |
1.01 |
.93 |
1.07 |
.99 |
| KLA/ATP | 1.01 |
.96 |
.97 |
.96 |
.97 |
.92 |
.99 |
|
Cbl | |
NM_007619 |
Casitas B-lineage lymphoma (Cbl), mRNA [NM_007619] |
KLA | 1.23 |
1.22 |
1.54 |
1.84 |
2.25 |
2.58 |
2.75 |
| ATP | 1.04 |
1.12 |
1.07 |
1.53 |
1.55 |
2.12 |
3.23 |
| KLA/ATP | 1.23 |
1.20 |
1.22 |
1.44 |
1.31 |
1.88 |
6.28 |
|
Cblb | |
AK045005 |
9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018P07 product:hypothetical protein, full insert sequence. [AK045005] |
KLA | 1.16 |
1.11 |
1.15 |
1.10 |
1.16 |
.98 |
.93 |
| ATP | 1.16 |
1.23 |
.98 |
1.28 |
1.34 |
.73 |
1.55 |
| KLA/ATP | 1.26 |
1.60 |
1.64 |
1.23 |
1.01 |
.91 |
1.05 |
|
Cblb | |
AK084162 |
12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230004I05 product:unclassifiable, full insert sequence. [AK084162] |
KLA | .97 |
.98 |
1.02 |
1.01 |
.84 |
1.02 |
1.03 |
| ATP | 1.03 |
1.02 |
.98 |
1.09 |
1.05 |
.96 |
.96 |
| KLA/ATP | 1.07 |
.95 |
.91 |
.98 |
.98 |
1.01 |
1.00 |
|
Cblc | |
NM_023224 |
Casitas B-lineage lymphoma c (Cblc), mRNA [NM_023224] |
KLA | 1.02 |
.98 |
1.01 |
1.02 |
1.00 |
.99 |
1.05 |
| ATP | .94 |
.95 |
.97 |
1.04 |
.99 |
.97 |
.99 |
| KLA/ATP | 1.00 |
1.01 |
.96 |
.97 |
.94 |
.92 |
.99 |
|
Crk | |
NM_133656 |
v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] |
KLA | 1.29 |
1.32 |
1.41 |
1.38 |
1.75 |
1.59 |
1.52 |
| ATP | 1.08 |
1.17 |
1.01 |
.93 |
1.27 |
2.11 |
1.70 |
| KLA/ATP | 1.37 |
1.49 |
1.14 |
1.09 |
1.21 |
1.69 |
2.32 |
|
Crkl | |
NM_007764 |
v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] |
KLA | 1.85 |
1.97 |
2.08 |
1.73 |
1.66 |
1.64 |
1.36 |
| ATP | .97 |
.94 |
.78 |
.74 |
1.46 |
1.89 |
1.46 |
| KLA/ATP | 1.92 |
1.88 |
1.18 |
1.44 |
1.67 |
2.65 |
2.72 |
|
Eif4e | |
NM_007917 |
eukaryotic translation initiation factor 4E (Eif4e), mRNA [NM_007917] |
KLA | 1.22 |
1.06 |
.94 |
.97 |
.83 |
.85 |
1.18 |
| ATP | 1.00 |
1.01 |
1.27 |
1.27 |
2.61 |
2.08 |
.97 |
| KLA/ATP | .95 |
1.04 |
1.37 |
1.16 |
1.50 |
1.28 |
.73 |
|
Eif4e2 | |
NM_001039169 |
eukaryotic translation initiation factor 4E member 2 (Eif4e2), transcript variant 2, mRNA [NM_001039169] |
KLA | 1.53 |
1.51 |
1.54 |
1.52 |
1.55 |
1.49 |
1.55 |
| ATP | 1.02 |
1.08 |
1.12 |
1.45 |
1.61 |
1.51 |
1.15 |
| KLA/ATP | 1.56 |
1.60 |
1.59 |
1.90 |
1.90 |
1.75 |
1.68 |
|
Eif4e2 | |
NM_023314 |
eukaryotic translation initiation factor 4E member 2 (Eif4e2), transcript variant 3, mRNA [NM_023314] |
KLA | 1.42 |
1.40 |
1.43 |
1.35 |
1.58 |
1.65 |
1.42 |
| ATP | 1.06 |
1.06 |
1.04 |
.98 |
1.41 |
2.07 |
2.04 |
| KLA/ATP | 1.46 |
1.48 |
1.40 |
1.45 |
1.64 |
2.12 |
2.30 |
|
Eif4ebp1
| |
NM_007918 |
eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1), mRNA [NM_007918] |
KLA | .66 |
.64 |
.59 |
.67 |
.81 |
.97 |
.97 |
| ATP | .97 |
.94 |
1.10 |
1.05 |
1.99 |
1.60 |
.91 |
| KLA/ATP | .62 |
.61 |
.68 |
.68 |
1.50 |
1.24 |
.95 |
|
Elk1 | |
AK082260 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] |
KLA | 1.02 |
1.01 |
1.01 |
.97 |
1.00 |
1.03 |
1.06 |
| ATP | 1.02 |
1.07 |
1.06 |
1.03 |
1.02 |
1.02 |
1.00 |
| KLA/ATP | 1.08 |
.99 |
.97 |
1.01 |
1.02 |
1.06 |
.95 |
|
Exoc7 | |
NM_016857 |
exocyst complex component 7 (Exoc7), mRNA [NM_016857] |
KLA | 1.12 |
1.15 |
1.17 |
1.05 |
1.15 |
1.19 |
1.08 |
| ATP | .99 |
.96 |
1.07 |
1.18 |
.78 |
.70 |
1.13 |
| KLA/ATP | 1.09 |
1.10 |
1.22 |
1.22 |
.89 |
.78 |
1.34 |
|
Fasn | |
NM_007988 |
fatty acid synthase (Fasn), mRNA [NM_007988] |
KLA | .51 |
.49 |
.46 |
.44 |
.41 |
.35 |
.41 |
| ATP | .98 |
.93 |
.98 |
.96 |
.83 |
.67 |
.62 |
| KLA/ATP | .52 |
.47 |
.48 |
.58 |
.51 |
.44 |
.25 |
|
Fbp1 | |
NM_019395 |
fructose bisphosphatase 1 (Fbp1), mRNA [NM_019395] |
KLA | .91 |
.95 |
1.03 |
1.01 |
1.00 |
1.02 |
.80 |
| ATP | .96 |
.96 |
.99 |
.95 |
.86 |
.84 |
.64 |
| KLA/ATP | .88 |
.96 |
.87 |
.92 |
.92 |
.84 |
.70 |
|
Fbp2 | |
NM_007994 |
fructose bisphosphatase 2 (Fbp2), mRNA [NM_007994] |
KLA | 1.03 |
1.03 |
.95 |
1.02 |
1.02 |
1.03 |
1.06 |
| ATP | 1.03 |
1.03 |
1.05 |
1.01 |
.97 |
1.01 |
1.17 |
| KLA/ATP | .96 |
.92 |
1.06 |
.85 |
1.07 |
.97 |
1.12 |
|
Flot1 | |
NM_008027 |
flotillin 1 (Flot1), mRNA [NM_008027] |
KLA | 1.01 |
1.10 |
1.16 |
1.16 |
1.82 |
2.12 |
1.71 |
| ATP | 1.02 |
1.03 |
.75 |
.90 |
.84 |
.75 |
1.19 |
| KLA/ATP | 1.14 |
1.09 |
.87 |
1.13 |
1.05 |
1.02 |
.88 |
|
Flot2 | |
NM_008028 |
flotillin 2 (Flot2), transcript variant 2, mRNA [NM_008028] |
KLA | .93 |
.97 |
.99 |
1.01 |
1.15 |
.97 |
1.15 |
| ATP | 1.25 |
1.45 |
.81 |
1.22 |
1.04 |
.87 |
.76 |
| KLA/ATP | 1.03 |
1.14 |
.64 |
1.06 |
.71 |
.92 |
1.19 |
|
Foxo1 | |
NM_019739 |
forkhead box O1 (Foxo1), mRNA [NM_019739] |
KLA | .60 |
.55 |
.60 |
.58 |
.49 |
.60 |
.71 |
| ATP | .96 |
1.03 |
1.08 |
1.03 |
2.49 |
1.70 |
.98 |
| KLA/ATP | .56 |
.58 |
.67 |
.83 |
1.47 |
1.57 |
.97 |
|
Frap1 | |
NM_020009 |
FK506 binding protein 12-rapamycin associated protein 1 (Frap1), mRNA [NM_020009] |
KLA | 1.37 |
1.32 |
1.46 |
1.57 |
1.83 |
1.29 |
1.28 |
| ATP | 1.12 |
1.07 |
.95 |
.91 |
.80 |
.77 |
1.03 |
| KLA/ATP | 1.45 |
1.51 |
1.50 |
1.11 |
.89 |
.87 |
1.01 |
|
G6pc | |
NM_008061 |
glucose-6-phosphatase, catalytic (G6pc), mRNA [NM_008061] |
KLA | .96 |
.94 |
1.04 |
1.07 |
1.09 |
1.06 |
1.02 |
| ATP | .98 |
1.05 |
1.09 |
1.04 |
1.05 |
1.00 |
1.01 |
| KLA/ATP | 1.03 |
1.05 |
1.06 |
.96 |
1.02 |
1.00 |
.99 |
|
G6pc2 | |
NM_021331 |
glucose-6-phosphatase, catalytic, 2 (G6pc2), mRNA [NM_021331] |
KLA | .99 |
1.03 |
1.00 |
.98 |
.95 |
1.02 |
.98 |
| ATP | .95 |
1.06 |
.97 |
1.08 |
1.16 |
1.26 |
1.04 |
| KLA/ATP | .94 |
.99 |
1.05 |
6.99 |
3.55 |
1.48 |
1.11 |
|
G6pc3 | |
NM_175935 |
glucose 6 phosphatase, catalytic, 3 (G6pc3), mRNA [NM_175935] |
KLA | .88 |
.89 |
.89 |
.80 |
.75 |
.68 |
.88 |
| ATP | .99 |
1.05 |
.95 |
1.14 |
.92 |
.64 |
.81 |
| KLA/ATP | .92 |
.90 |
.79 |
.94 |
.70 |
.62 |
.58 |
|
Gck | |
NM_010292 |
glucokinase (Gck), mRNA [NM_010292] |
KLA | 1.03 |
.99 |
1.04 |
1.02 |
.97 |
.98 |
1.00 |
| ATP | 1.01 |
.97 |
1.08 |
.99 |
1.06 |
.98 |
.96 |
| KLA/ATP | 1.06 |
1.01 |
.96 |
.98 |
.98 |
1.01 |
1.01 |
|
Grb2 | |
NM_008163 |
growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] |
KLA | .92 |
.88 |
.90 |
1.27 |
1.43 |
1.22 |
1.00 |
| ATP | 1.02 |
.83 |
.51 |
.42 |
.92 |
.70 |
.57 |
| KLA/ATP | .84 |
.77 |
.61 |
.56 |
1.56 |
1.49 |
.52 |
|
Grb2 | |
U07617 |
Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] |
KLA | .83 |
.80 |
.95 |
1.13 |
1.38 |
1.36 |
1.06 |
| ATP | .84 |
.74 |
.51 |
.41 |
.82 |
.74 |
.59 |
| KLA/ATP | .77 |
.70 |
.57 |
.54 |
1.49 |
1.39 |
.53 |
|
Gsk3b | |
NM_019827 |
glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] |
KLA | 1.06 |
1.03 |
1.11 |
1.01 |
1.26 |
1.28 |
1.26 |
| ATP | 1.18 |
1.27 |
1.15 |
2.07 |
2.37 |
2.32 |
1.67 |
| KLA/ATP | 1.15 |
1.21 |
.98 |
1.50 |
1.67 |
2.50 |
2.99 |
|
Gys1 | |
NM_030678 |
glycogen synthase 1, muscle (Gys1), mRNA [NM_030678] |
KLA | .89 |
.89 |
.88 |
.80 |
.91 |
1.07 |
1.78 |
| ATP | 1.02 |
1.15 |
.91 |
1.01 |
.72 |
.73 |
1.14 |
| KLA/ATP | .96 |
.94 |
.73 |
.87 |
.63 |
.64 |
1.24 |
|
Gys2 | |
NM_145572 |
glycogen synthase 2 (Gys2), mRNA [NM_145572] |
KLA | 1.01 |
.96 |
.99 |
1.06 |
1.02 |
1.00 |
.92 |
| ATP | .99 |
.98 |
.98 |
1.02 |
.95 |
1.12 |
1.10 |
| KLA/ATP | 1.03 |
.97 |
1.00 |
1.03 |
1.01 |
1.05 |
1.09 |
|
Hk1 | |
J05277 |
gb|Mouse hexokinase mRNA, complete cds [J05277] |
KLA | 1.49 |
1.45 |
1.66 |
1.78 |
1.51 |
1.29 |
.99 |
| ATP | 1.11 |
1.05 |
1.15 |
1.20 |
2.31 |
2.17 |
1.09 |
| KLA/ATP | 1.63 |
1.51 |
1.70 |
1.47 |
1.94 |
1.92 |
1.40 |
|
Hk1 | |
NM_010438 |
hexokinase 1 (Hk1), nuclear gene encoding mitochondrial protein, mRNA [NM_010438] |
KLA | 1.58 |
1.75 |
2.05 |
1.84 |
1.96 |
1.67 |
1.31 |
| ATP | 1.06 |
1.25 |
1.01 |
1.49 |
2.23 |
1.79 |
1.20 |
| KLA/ATP | 1.87 |
1.96 |
1.51 |
1.93 |
1.71 |
1.94 |
1.72 |
|
Hk2 | |
NM_013820 |
hexokinase 2 (Hk2), mRNA [NM_013820] |
KLA | 4.09 |
4.09 |
3.17 |
2.37 |
1.53 |
1.62 |
2.02 |
| ATP | .98 |
.92 |
1.08 |
2.24 |
3.82 |
3.86 |
.97 |
| KLA/ATP | 4.07 |
3.94 |
4.17 |
3.53 |
5.42 |
4.65 |
1.54 |
|
Hk3 | |
NM_001033245 |
hexokinase 3 (Hk3), nuclear gene encoding mitochondrial protein, mRNA [NM_001033245] |
KLA | 1.52 |
1.68 |
1.94 |
1.85 |
2.21 |
2.89 |
1.98 |
| ATP | 1.01 |
1.07 |
.87 |
.99 |
1.01 |
1.26 |
2.62 |
| KLA/ATP | 1.63 |
1.74 |
1.67 |
1.69 |
1.44 |
2.01 |
3.53 |
|
Hkdc1 | |
NM_145419 |
hexokinase domain containing 1 (Hkdc1), mRNA [NM_145419] |
KLA | 1.10 |
1.08 |
1.12 |
1.12 |
1.02 |
1.07 |
1.04 |
| ATP | .96 |
1.04 |
1.06 |
4.28 |
10.50 |
3.91 |
1.34 |
| KLA/ATP | .98 |
1.04 |
1.14 |
5.33 |
12.44 |
8.68 |
1.77 |
|
Hras1 | |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Ikbkb | |
NM_010546 |
inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] |
KLA | 1.88 |
2.10 |
2.14 |
1.83 |
1.73 |
1.31 |
1.19 |
| ATP | .81 |
.74 |
.55 |
.49 |
.59 |
1.05 |
.96 |
| KLA/ATP | 1.86 |
1.73 |
1.39 |
1.12 |
.89 |
1.17 |
1.24 |
|
Inppl1 | |
NM_010567 |
inositol polyphosphate phosphatase-like 1 (Inppl1), transcript variant 1, mRNA [NM_010567] |
KLA | .82 |
.80 |
.73 |
.81 |
.79 |
.72 |
.94 |
| ATP | 1.05 |
1.04 |
.69 |
.58 |
.56 |
.87 |
.98 |
| KLA/ATP | .90 |
.83 |
.58 |
.46 |
.87 |
1.07 |
1.34 |
|
Ins1 | |
NM_008386 |
insulin I (Ins1), mRNA [NM_008386] |
KLA | 1.00 |
.99 |
.99 |
1.03 |
1.01 |
.98 |
1.06 |
| ATP | .97 |
1.03 |
1.00 |
1.03 |
.99 |
1.07 |
1.05 |
| KLA/ATP | 1.03 |
.93 |
.98 |
1.04 |
1.07 |
1.03 |
1.01 |
|
Ins2 | |
NM_008387 |
insulin II (Ins2), mRNA [NM_008387] |
KLA | .99 |
1.00 |
1.00 |
1.01 |
1.00 |
1.02 |
1.00 |
| ATP | 1.01 |
.99 |
1.00 |
1.00 |
.98 |
.99 |
1.01 |
| KLA/ATP | .99 |
1.01 |
1.00 |
.98 |
.99 |
.99 |
.98 |
|
Insr | |
NM_010568 |
insulin receptor (Insr), mRNA [NM_010568] |
KLA | .75 |
.81 |
.77 |
.69 |
.69 |
.69 |
.83 |
| ATP | 1.07 |
1.06 |
.88 |
.79 |
.73 |
.77 |
.83 |
| KLA/ATP | .80 |
.80 |
.72 |
.71 |
.64 |
.64 |
.70 |
|
Irs1 | |
NM_010570 |
insulin receptor substrate 1 (Irs1), mRNA [NM_010570] |
KLA | .97 |
.96 |
.99 |
1.01 |
.93 |
.94 |
.94 |
| ATP | 1.00 |
.99 |
1.02 |
.96 |
.96 |
.94 |
.91 |
| KLA/ATP | .96 |
.96 |
.98 |
.96 |
.97 |
.98 |
.92 |
|
Irs3 | |
NM_010571 |
insulin receptor substrate 3 (Irs3), mRNA [NM_010571] |
KLA | 1.02 |
.92 |
1.00 |
.97 |
.93 |
.94 |
.95 |
| ATP | .95 |
1.06 |
1.05 |
.88 |
.95 |
.99 |
.99 |
| KLA/ATP | .89 |
.88 |
.96 |
.94 |
.88 |
.90 |
.97 |
|
Irs4 | |
NM_010572 |
insulin receptor substrate 4 (Irs4), mRNA [NM_010572] |
KLA | 1.06 |
1.14 |
1.08 |
1.15 |
1.09 |
1.22 |
1.06 |
| ATP | .99 |
.98 |
1.19 |
1.10 |
1.15 |
1.18 |
1.05 |
| KLA/ATP | 1.02 |
1.10 |
1.26 |
1.19 |
1.22 |
1.32 |
1.18 |
|
Kras | |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
Lipe | |
NM_010719 |
lipase, hormone sensitive (Lipe), transcript variant 1, mRNA [NM_010719] |
KLA | 2.36 |
2.54 |
3.08 |
2.85 |
2.98 |
2.82 |
1.81 |
| ATP | 1.06 |
1.13 |
.98 |
1.19 |
.96 |
1.61 |
2.04 |
| KLA/ATP | 2.71 |
2.84 |
2.49 |
2.92 |
1.84 |
2.62 |
3.39 |
|
Map2k1 | |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
Map2k2 | |
NM_023138 |
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] |
KLA | .96 |
1.01 |
1.09 |
.99 |
1.11 |
1.15 |
1.42 |
| ATP | 1.07 |
1.05 |
.74 |
.86 |
1.04 |
1.16 |
1.21 |
| KLA/ATP | 1.14 |
1.03 |
.68 |
.78 |
.85 |
1.01 |
1.20 |
|
Mapk1 | |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 | |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk10 | |
AK076990 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] |
KLA | 1.03 |
1.05 |
.98 |
1.04 |
.94 |
.95 |
1.02 |
| ATP | 1.00 |
.99 |
1.06 |
.97 |
1.01 |
.96 |
.99 |
| KLA/ATP | 1.07 |
1.01 |
.95 |
1.05 |
.82 |
.95 |
.87 |
|
Mapk10 | |
NM_009158 |
mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] |
KLA | .95 |
1.00 |
.97 |
1.01 |
.99 |
1.01 |
.95 |
| ATP | 1.01 |
1.02 |
.98 |
1.01 |
1.04 |
1.01 |
.99 |
| KLA/ATP | 1.05 |
.99 |
1.01 |
.98 |
.92 |
.97 |
.98 |
|
Mapk3 | |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mapk8 | |
AK162915 |
adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] |
KLA | .94 |
.86 |
.80 |
.83 |
.77 |
.85 |
.83 |
| ATP | 1.08 |
1.12 |
.94 |
.80 |
.83 |
.71 |
.75 |
| KLA/ATP | .83 |
.81 |
.80 |
.74 |
.74 |
.75 |
.67 |
|
Mapk8 | |
AK163829 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] |
KLA | .65 |
.61 |
.66 |
.70 |
.90 |
1.02 |
1.03 |
| ATP | .99 |
.94 |
1.68 |
1.44 |
1.75 |
1.84 |
1.10 |
| KLA/ATP | .63 |
.67 |
1.11 |
1.00 |
2.01 |
1.68 |
1.15 |
|
Mapk8 | |
NM_016700 |
mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] |
KLA | .96 |
1.00 |
.94 |
.96 |
.94 |
.99 |
1.04 |
| ATP | 1.01 |
1.05 |
1.01 |
.99 |
1.03 |
.98 |
1.02 |
| KLA/ATP | .96 |
.97 |
.96 |
.97 |
.93 |
.94 |
.96 |
|
Mapk9 | |
NM_016961 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] |
KLA | 1.28 |
1.37 |
1.59 |
1.60 |
1.61 |
1.43 |
1.38 |
| ATP | 1.03 |
.99 |
.74 |
.71 |
.79 |
1.20 |
1.01 |
| KLA/ATP | 1.53 |
1.30 |
1.07 |
.99 |
.83 |
1.10 |
1.40 |
|
Mapk9 | |
NM_207692 |
mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] |
KLA | 1.39 |
1.53 |
1.69 |
1.69 |
1.55 |
1.44 |
1.51 |
| ATP | .95 |
.92 |
.75 |
.85 |
.70 |
1.46 |
1.17 |
| KLA/ATP | 1.37 |
1.35 |
.99 |
1.18 |
.91 |
1.22 |
1.62 |
|
Mknk1 | |
NM_021461 |
MAP kinase-interacting serine/threonine kinase 1 (Mknk1), mRNA [NM_021461] |
KLA | .78 |
.81 |
.88 |
.86 |
.98 |
1.12 |
.93 |
| ATP | 1.04 |
1.03 |
1.03 |
1.07 |
.70 |
.67 |
1.09 |
| KLA/ATP | .83 |
.83 |
.81 |
.84 |
.66 |
.88 |
1.12 |
|
Mknk2 | |
NM_021462 |
MAP kinase-interacting serine/threonine kinase 2 (Mknk2), mRNA [NM_021462] |
KLA | .19 |
.18 |
.16 |
.15 |
.20 |
.50 |
.62 |
| ATP | .89 |
.86 |
1.35 |
2.05 |
1.76 |
1.52 |
1.29 |
| KLA/ATP | .19 |
.17 |
.32 |
.99 |
1.61 |
2.33 |
1.97 |
|
Mm.21312 8 | |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.22094 6 | |
27545180 |
Unknown |
KLA | 1.00 |
.93 |
.97 |
1.05 |
1.06 |
1.29 |
1.13 |
| ATP | .90 |
.94 |
1.25 |
1.18 |
.85 |
.62 |
1.20 |
| KLA/ATP | .86 |
.99 |
1.14 |
.99 |
.83 |
.70 |
1.26 |
|
Mm.25381 9 | |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.26687 1 | |
80978931 |
Unknown |
KLA | .67 |
.63 |
.70 |
.83 |
1.66 |
1.43 |
1.54 |
| ATP | 1.20 |
1.24 |
1.22 |
1.26 |
1.80 |
.81 |
1.02 |
| KLA/ATP | .63 |
.56 |
.83 |
1.06 |
1.26 |
.70 |
1.34 |
|
Mm.27791 6 | |
133505844 |
Unknown |
KLA | .72 |
.68 |
.80 |
1.17 |
1.52 |
1.33 |
1.19 |
| ATP | .85 |
.76 |
.85 |
.58 |
1.10 |
1.47 |
.53 |
| KLA/ATP | .61 |
.62 |
.79 |
.68 |
1.96 |
1.74 |
.48 |
|
Mm.30616 3 | |
31543508 |
Unknown |
KLA | .75 |
.79 |
.72 |
.74 |
.73 |
.95 |
1.15 |
| ATP | .93 |
.93 |
1.13 |
1.15 |
1.30 |
1.17 |
1.64 |
| KLA/ATP | .78 |
.83 |
.82 |
.86 |
1.02 |
1.17 |
1.18 |
|
Mm.3159 | |
77404187 |
Unknown |
KLA | .96 |
.95 |
1.06 |
1.00 |
1.00 |
.91 |
1.05 |
| ATP | 1.06 |
.97 |
.97 |
.96 |
1.02 |
.90 |
1.05 |
| KLA/ATP | .92 |
.99 |
.96 |
.99 |
.99 |
.99 |
.98 |
|
Mm.4387 | |
133892666 |
Unknown |
KLA | .85 |
.87 |
.85 |
.89 |
.77 |
.91 |
1.18 |
| ATP | 1.01 |
1.01 |
.87 |
1.07 |
.75 |
.86 |
.93 |
| KLA/ATP | .88 |
.86 |
.77 |
.81 |
.72 |
.91 |
.84 |
|
Mm.44266 8 | |
21703801 |
Unknown |
KLA | .22 |
.18 |
.13 |
.12 |
.11 |
.16 |
.29 |
| ATP | .80 |
.65 |
.69 |
.53 |
.38 |
.54 |
.41 |
| KLA/ATP | .17 |
.15 |
.13 |
.11 |
.28 |
.48 |
.12 |
|
Mm.45825 9 | |
116292181 |
Unknown |
KLA | .84 |
.86 |
.91 |
.85 |
.98 |
.98 |
1.00 |
| ATP | 1.05 |
1.06 |
.94 |
.95 |
1.00 |
.89 |
.89 |
| KLA/ATP | .92 |
.84 |
.87 |
.93 |
.91 |
.92 |
.82 |
|
Mm.47273 6 | |
94367764 |
Unknown |
KLA | .83 |
.88 |
1.22 |
1.49 |
1.09 |
.93 |
.46 |
| ATP | .80 |
.57 |
.51 |
.23 |
.51 |
.97 |
.74 |
| KLA/ATP | .66 |
.62 |
1.00 |
.65 |
2.02 |
1.08 |
.37 |
|
Mm.81698
| |
158937287 |
Unknown |
KLA | .95 |
1.02 |
1.04 |
.98 |
1.01 |
1.04 |
1.08 |
| ATP | 1.00 |
1.03 |
.97 |
1.00 |
1.03 |
.98 |
.96 |
| KLA/ATP | 1.07 |
1.00 |
.94 |
.98 |
1.03 |
1.05 |
.97 |
|
Nras | |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
Pck2 | |
NM_028994 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) (Pck2), nuclear gene encoding mitochondrial protein, mRNA [NM_028994] |
KLA | .40 |
.37 |
.32 |
.28 |
.37 |
.56 |
.55 |
| ATP | .99 |
.96 |
.86 |
.94 |
1.02 |
.57 |
.77 |
| KLA/ATP | .40 |
.37 |
.31 |
.35 |
.42 |
.35 |
.46 |
|
Pde3a | |
AK004638 |
adult male lung cDNA, RIKEN full-length enriched library, clone:1200007J10 product:phosphodiesterase 3A, cGMP inhibited, full insert sequence. [AK004638] |
KLA | .96 |
.94 |
.95 |
1.07 |
1.01 |
1.00 |
1.03 |
| ATP | 1.02 |
.95 |
.96 |
1.07 |
.97 |
.96 |
1.01 |
| KLA/ATP | 1.00 |
1.00 |
1.02 |
.94 |
.98 |
.99 |
1.01 |
|
Pde3a | |
AK052718 |
0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630035A07 product:inferred: phosphodiesterase 3A, cGMP inhibited, full insert sequence. [AK052718] |
KLA | .93 |
1.02 |
.94 |
1.00 |
.98 |
1.03 |
.96 |
| ATP | 1.03 |
.96 |
1.00 |
.98 |
1.00 |
1.03 |
1.01 |
| KLA/ATP | .98 |
1.06 |
1.08 |
1.03 |
.94 |
.98 |
.89 |
|
Pde3a | |
NM_018779 |
phosphodiesterase 3A, cGMP inhibited (Pde3a), mRNA [NM_018779] |
KLA | 1.01 |
1.09 |
.98 |
.98 |
.93 |
1.03 |
1.09 |
| ATP | .99 |
.97 |
1.04 |
1.05 |
.96 |
.96 |
1.06 |
| KLA/ATP | 1.06 |
.97 |
.94 |
1.09 |
1.00 |
1.06 |
.96 |
|
Pde3b | |
AK044183 |
10 days neonate cortex cDNA, RIKEN full-length enriched library, clone:A830097M14 product:phosphodiesterase 3B, cGMP-inhibited, full insert sequence. [AK044183] |
KLA | .98 |
.99 |
1.04 |
.99 |
.93 |
1.01 |
.96 |
| ATP | 1.08 |
.96 |
.92 |
.93 |
.93 |
.90 |
.93 |
| KLA/ATP | .97 |
.94 |
.95 |
.89 |
.92 |
.89 |
.95 |
|
Pde3b | |
NM_011055 |
phosphodiesterase 3B, cGMP-inhibited (Pde3b), mRNA [NM_011055] |
KLA | 1.02 |
1.01 |
.95 |
1.00 |
.88 |
.75 |
.59 |
| ATP | 1.12 |
1.20 |
1.09 |
1.04 |
.71 |
.95 |
.81 |
| KLA/ATP | .90 |
.92 |
1.00 |
.94 |
.74 |
.85 |
.93 |
|
Pdpk1 | |
NM_011062 |
3-phosphoinositide dependent protein kinase-1 (Pdpk1), transcript variant 1, mRNA [NM_011062] |
KLA | .90 |
.90 |
.84 |
1.00 |
1.32 |
1.19 |
1.15 |
| ATP | 1.05 |
1.09 |
1.04 |
1.14 |
1.31 |
.97 |
1.17 |
| KLA/ATP | .90 |
.89 |
.91 |
1.02 |
1.27 |
.96 |
1.42 |
|
Phka1 | |
NM_008832 |
phosphorylase kinase alpha 1 (Phka1), transcript variant 1, mRNA [NM_008832] |
KLA | .89 |
.77 |
.77 |
.83 |
.74 |
.79 |
.89 |
| ATP | 1.10 |
1.03 |
.90 |
.88 |
.69 |
.72 |
.79 |
| KLA/ATP | .83 |
.78 |
.80 |
.70 |
.67 |
.76 |
.66 |
|
Phka2 | |
AK045618 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230216B06 product:PHOSPHORYLASE B KINASE ALPHA REGULATORY CHAIN, LIVER ISOFORM (PHOSPHORYLASE KINASE ALPHA L SUBUNIT)homolog [Homo sapiens], full insert sequ |
KLA | .48 |
.47 |
.52 |
.56 |
.57 |
.60 |
.48 |
| ATP | .79 |
.70 |
.60 |
.56 |
.50 |
.49 |
.58 |
| KLA/ATP | .45 |
.46 |
.53 |
.55 |
.58 |
.48 |
.47 |
|
Phka2 | |
NM_172783 |
phosphorylase kinase alpha 2 (Phka2), mRNA [NM_172783] |
KLA | .66 |
.67 |
.61 |
.52 |
.46 |
.48 |
.52 |
| ATP | 1.06 |
1.17 |
.74 |
.86 |
.45 |
.32 |
.60 |
| KLA/ATP | .76 |
.68 |
.42 |
.51 |
.31 |
.31 |
.50 |
|
Phkb | |
AK089493 |
B6-derived CD11 +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F730039M10 product:similar to phosphorylase kinase (EC 2.7.1.38) beta chain [Homo sapiens], full insert sequence. [AK089493] |
KLA | .90 |
.83 |
.71 |
.84 |
1.04 |
.89 |
.91 |
| ATP | .96 |
1.05 |
.83 |
.72 |
.77 |
.76 |
.85 |
| KLA/ATP | .87 |
.87 |
.76 |
.71 |
.78 |
.71 |
.77 |
|
Phkb | |
NM_199446 |
phosphorylase kinase beta (Phkb), mRNA [NM_199446] |
KLA | .94 |
.94 |
.95 |
.93 |
.83 |
.77 |
.79 |
| ATP | .96 |
1.02 |
.94 |
.86 |
.51 |
.38 |
.60 |
| KLA/ATP | .91 |
.93 |
.76 |
.71 |
.45 |
.38 |
.44 |
|
Phkg1 | |
NM_011079 |
phosphorylase kinase gamma 1 (Phkg1), mRNA [NM_011079] |
KLA | 1.00 |
.98 |
1.06 |
1.06 |
.95 |
.99 |
.94 |
| ATP | 1.02 |
.98 |
.91 |
.99 |
1.00 |
.91 |
.96 |
| KLA/ATP | 1.02 |
1.11 |
1.01 |
.99 |
1.00 |
.92 |
1.09 |
|
Phkg2 | |
AK089062 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430038C01 product:5phosphorylase kinase, gamma 2 (testis), full insert sequence [AK089062] |
KLA | .93 |
.90 |
.88 |
.86 |
.99 |
.79 |
.89 |
| ATP | 1.10 |
1.05 |
.68 |
.73 |
1.05 |
.92 |
.98 |
| KLA/ATP | .87 |
.84 |
.69 |
.79 |
.93 |
.97 |
1.10 |
|
Phkg2 | |
NM_026888 |
phosphorylase kinase, gamma 2 (testis) (Phkg2), mRNA [NM_026888] |
KLA | .88 |
.86 |
.98 |
.96 |
1.13 |
1.02 |
.92 |
| ATP | 1.19 |
1.12 |
1.02 |
1.23 |
1.17 |
1.23 |
1.22 |
| KLA/ATP | 1.04 |
1.06 |
1.00 |
1.13 |
1.25 |
1.33 |
1.64 |
|
Pik3ca | |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca | |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb | |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd | |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd | |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg | |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 | |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 | |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 | |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 | |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Pklr | |
NM_013631 |
pyruvate kinase liver and red blood cell (Pklr), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA [NM_013631] |
KLA | 1.06 |
1.01 |
1.12 |
1.00 |
.98 |
1.01 |
1.07 |
| ATP | .98 |
.94 |
1.05 |
1.06 |
1.01 |
1.06 |
1.10 |
| KLA/ATP | .97 |
1.00 |
1.04 |
.95 |
.89 |
1.05 |
.97 |
|
Ppargc1a
| |
AK032149 |
adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430402E12 product:hypothetical protein, full insert sequence [AK032149] |
KLA | .98 |
1.02 |
1.01 |
.93 |
.98 |
.97 |
.88 |
| ATP | .94 |
1.02 |
1.05 |
.95 |
.98 |
.99 |
1.05 |
| KLA/ATP | .96 |
1.01 |
1.01 |
1.02 |
1.01 |
.99 |
1.08 |
|
Ppargc1a
| |
NM_008904 |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha (Ppargc1a), mRNA [NM_008904] |
KLA | .99 |
1.00 |
.91 |
.99 |
1.04 |
1.00 |
1.03 |
| ATP | 1.00 |
.93 |
1.02 |
1.01 |
1.04 |
1.07 |
1.03 |
| KLA/ATP | 1.03 |
.95 |
1.02 |
1.01 |
1.04 |
1.10 |
1.06 |
|
Ppp1ca | |
NM_031868 |
protein phosphatase 1, catalytic subunit, alpha isoform (Ppp1ca), mRNA [NM_031868] |
KLA | .89 |
.93 |
.93 |
.86 |
.95 |
1.07 |
1.20 |
| ATP | 1.04 |
1.07 |
.93 |
1.02 |
1.01 |
.89 |
1.10 |
| KLA/ATP | .98 |
.93 |
.74 |
.91 |
.84 |
1.01 |
1.34 |
|
Ppp1cb | |
NM_172707 |
protein phosphatase 1, catalytic subunit, beta isoform (Ppp1cb), mRNA [NM_172707] |
KLA | 1.12 |
1.08 |
1.05 |
1.02 |
.89 |
.84 |
.94 |
| ATP | .89 |
.87 |
.75 |
.55 |
.73 |
1.14 |
.69 |
| KLA/ATP | .92 |
.94 |
.80 |
.64 |
.64 |
.83 |
.65 |
|
Ppp1cc | |
NM_013636 |
protein phosphatase 1, catalytic subunit, gamma isoform (Ppp1cc), mRNA [NM_013636] |
KLA | .51 |
.51 |
.49 |
.48 |
.53 |
.64 |
.64 |
| ATP | 1.02 |
1.01 |
.85 |
.79 |
.72 |
.89 |
.95 |
| KLA/ATP | .54 |
.49 |
.42 |
.43 |
.56 |
.76 |
.81 |
|
Ppp1r3b | |
NM_177741 |
protein phosphatase 1, regulatory (inhibitor) subunit 3B (Ppp1r3b), mRNA [NM_177741] |
KLA | .53 |
.58 |
.62 |
.61 |
.65 |
.70 |
.65 |
| ATP | 1.04 |
.97 |
.80 |
.70 |
.79 |
.95 |
.91 |
| KLA/ATP | .60 |
.57 |
.59 |
.73 |
.83 |
.80 |
.61 |
|
Ppp1r3c | |
NM_016854 |
protein phosphatase 1, regulatory (inhibitor) subunit 3C (Ppp1r3c), mRNA [NM_016854] |
KLA | 1.00 |
.99 |
.98 |
1.07 |
1.01 |
.96 |
1.08 |
| ATP | 1.02 |
.99 |
.99 |
1.14 |
1.08 |
.98 |
1.01 |
| KLA/ATP | 1.00 |
1.02 |
.94 |
1.09 |
1.06 |
1.05 |
1.11 |
|
Ppp1r3d | |
NM_001085501 |
protein phosphatase 1, regulatory subunit 3D (Ppp1r3d), mRNA [NM_001085501] |
KLA | .83 |
.93 |
1.20 |
1.43 |
1.22 |
.96 |
.47 |
| ATP | .95 |
.70 |
.61 |
.27 |
.51 |
.92 |
.75 |
| KLA/ATP | .80 |
.58 |
.91 |
.69 |
1.84 |
.92 |
.39 |
|
Prkaa1 | |
NM_001013367 |
protein kinase, AMP-activated, alpha 1 catalytic subunit (Prkaa1), mRNA [NM_001013367] |
KLA | 1.10 |
1.03 |
1.17 |
1.25 |
1.24 |
1.61 |
2.29 |
| ATP | 1.04 |
1.07 |
1.10 |
1.08 |
1.04 |
2.01 |
2.13 |
| KLA/ATP | 1.07 |
1.04 |
1.04 |
1.17 |
.95 |
1.90 |
3.90 |
|
Prkaa2 | |
NM_178143 |
protein kinase, AMP-activated, alpha 2 catalytic subunit (Prkaa2), mRNA [NM_178143] |
KLA | .93 |
.94 |
.94 |
.90 |
.92 |
.92 |
.99 |
| ATP | 1.00 |
1.14 |
.93 |
1.01 |
1.00 |
1.11 |
.98 |
| KLA/ATP | 1.00 |
.97 |
.99 |
1.01 |
.98 |
1.02 |
.98 |
|
Prkab1 | |
NM_031869 |
protein kinase, AMP-activated, beta 1 non-catalytic subunit (Prkab1), mRNA [NM_031869] |
KLA | .68 |
.70 |
.95 |
1.10 |
1.43 |
1.66 |
1.22 |
| ATP | 1.02 |
.93 |
.93 |
.95 |
.92 |
1.62 |
1.46 |
| KLA/ATP | .72 |
.73 |
.84 |
.85 |
1.12 |
1.68 |
2.36 |
|
Prkab2 | |
NM_182997 |
protein kinase, AMP-activated, beta 2 non-catalytic subunit (Prkab2), mRNA [NM_182997] |
KLA | .55 |
.56 |
.46 |
.65 |
.78 |
.68 |
.59 |
| ATP | .95 |
.74 |
.78 |
1.43 |
2.06 |
1.50 |
.70 |
| KLA/ATP | .60 |
.49 |
.51 |
.65 |
1.36 |
.94 |
.58 |
|
Prkaca | |
NM_008854 |
protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] |
KLA | .71 |
.74 |
.72 |
.70 |
.72 |
.84 |
.85 |
| ATP | 1.05 |
.98 |
.89 |
.92 |
.76 |
.60 |
1.02 |
| KLA/ATP | .79 |
.74 |
.55 |
.65 |
.60 |
.65 |
.93 |
|
Prkacb | |
NM_011100 |
protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] |
KLA | .69 |
.70 |
.66 |
.58 |
.51 |
.55 |
.59 |
| ATP | 1.02 |
1.19 |
.97 |
1.01 |
.69 |
.38 |
.56 |
| KLA/ATP | .72 |
.73 |
.57 |
.62 |
.47 |
.41 |
.45 |
|
Prkag1 | |
NM_016781 |
protein kinase, AMP-activated, gamma 1 non-catalytic subunit (Prkag1), mRNA [NM_016781] |
KLA | .66 |
.70 |
.71 |
.83 |
.92 |
1.02 |
1.02 |
| ATP | 1.06 |
1.00 |
.97 |
1.04 |
.81 |
1.09 |
1.16 |
| KLA/ATP | .67 |
.74 |
.75 |
.74 |
.76 |
1.15 |
1.37 |
|
Prkag2 | |
NM_145401 |
protein kinase, AMP-activated, gamma 2 non-catalytic subunit (Prkag2), mRNA [NM_145401] |
KLA | .41 |
.39 |
.30 |
.35 |
.30 |
.34 |
.45 |
| ATP | .88 |
.86 |
.65 |
.68 |
.46 |
.52 |
.47 |
| KLA/ATP | .39 |
.37 |
.32 |
.37 |
.38 |
.48 |
.30 |
|
Prkag3 | |
NM_153744 |
protein kinase, AMP-activated, gamma 3 non-catatlytic subunit (Prkag3), transcript variant 1, mRNA [NM_153744] |
KLA | 1.01 |
.99 |
1.03 |
1.04 |
1.12 |
1.00 |
1.15 |
| ATP | .97 |
1.07 |
1.10 |
1.11 |
1.05 |
1.09 |
1.04 |
| KLA/ATP | 1.06 |
1.02 |
1.11 |
1.15 |
1.11 |
1.07 |
.98 |
|
Prkar1a | |
NM_021880 |
protein kinase, cAMP dependent regulatory, type I, alpha (Prkar1a), mRNA [NM_021880] |
KLA | 1.03 |
1.01 |
1.14 |
.97 |
1.05 |
.93 |
.85 |
| ATP | 1.14 |
1.32 |
1.06 |
1.24 |
1.00 |
.62 |
.68 |
| KLA/ATP | 1.16 |
1.24 |
.83 |
1.13 |
.84 |
.79 |
.48 |
|
Prkar1b | |
NM_008923 |
protein kinase, cAMP dependent regulatory, type I beta (Prkar1b), mRNA [NM_008923] |
KLA | 1.02 |
1.05 |
.85 |
.95 |
.90 |
.98 |
1.26 |
| ATP | 1.05 |
1.12 |
.95 |
1.12 |
1.12 |
1.06 |
1.23 |
| KLA/ATP | 1.00 |
.97 |
.81 |
.90 |
.93 |
1.06 |
1.05 |
|
Prkar2a | |
NM_008924 |
protein kinase, cAMP dependent regulatory, type II alpha (Prkar2a), mRNA [NM_008924] |
KLA | .70 |
.65 |
.56 |
.52 |
.41 |
.48 |
.82 |
| ATP | 1.05 |
1.27 |
.85 |
1.05 |
.74 |
.70 |
.84 |
| KLA/ATP | .71 |
.72 |
.45 |
.56 |
.41 |
.51 |
.71 |
|
Prkar2b | |
NM_011158 |
protein kinase, cAMP dependent regulatory, type II beta (Prkar2b), mRNA [NM_011158] |
KLA | .83 |
.76 |
.76 |
.67 |
.34 |
.43 |
.62 |
| ATP | .82 |
.79 |
1.08 |
.71 |
.69 |
2.46 |
.55 |
| KLA/ATP | .65 |
.74 |
.95 |
.63 |
.42 |
.70 |
1.19 |
|
Prkci | |
NM_008857 |
protein kinase C, iota (Prkci), mRNA [NM_008857] |
KLA | .92 |
.84 |
.75 |
.59 |
.50 |
.66 |
.90 |
| ATP | 1.06 |
1.20 |
1.15 |
1.10 |
1.14 |
1.04 |
1.00 |
| KLA/ATP | .83 |
.92 |
.75 |
.78 |
.99 |
1.06 |
.80 |
|
Prkcz | |
NM_008860 |
protein kinase C, zeta (Prkcz), transcript variant 1, mRNA [NM_008860] |
KLA | .92 |
.90 |
1.00 |
.99 |
1.07 |
1.05 |
1.12 |
| ATP | 1.01 |
.95 |
.94 |
.93 |
1.04 |
1.04 |
.95 |
| KLA/ATP | .95 |
.94 |
.95 |
.94 |
.99 |
1.02 |
.98 |
|
Prkx | |
NM_016979 |
protein kinase, X-linked (Prkx), mRNA [NM_016979] |
KLA | 3.61 |
3.79 |
4.67 |
4.66 |
4.85 |
4.19 |
1.43 |
| ATP | .98 |
.90 |
.63 |
.61 |
1.12 |
1.90 |
1.29 |
| KLA/ATP | 3.56 |
3.36 |
2.62 |
2.06 |
2.26 |
2.87 |
2.31 |
|
Ptpn1 | |
NM_011201 |
protein tyrosine phosphatase, non-receptor type 1 (Ptpn1), mRNA [NM_011201] |
KLA | .91 |
.93 |
1.16 |
1.45 |
2.07 |
1.55 |
1.63 |
| ATP | 1.03 |
1.01 |
.83 |
.70 |
1.31 |
1.65 |
.92 |
| KLA/ATP | .93 |
.93 |
.98 |
1.02 |
1.99 |
2.02 |
1.03 |
|
Ptprf | |
NM_011213 |
protein tyrosine phosphatase, receptor type, F (Ptprf), mRNA [NM_011213] |
KLA | 1.28 |
1.42 |
1.29 |
1.27 |
1.17 |
1.19 |
1.27 |
| ATP | 1.09 |
1.11 |
1.27 |
1.29 |
1.53 |
2.24 |
2.95 |
| KLA/ATP | 1.31 |
1.42 |
1.28 |
1.33 |
1.25 |
1.50 |
1.60 |
|
Pygb | |
NM_153781 |
brain glycogen phosphorylase (Pygb), mRNA [NM_153781] |
KLA | .91 |
.83 |
.91 |
.78 |
.88 |
.87 |
.81 |
| ATP | 1.12 |
1.17 |
.92 |
1.03 |
.75 |
.51 |
.83 |
| KLA/ATP | .92 |
.91 |
.81 |
.88 |
.67 |
.61 |
.63 |
|
Pygl | |
AK083075 |
12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530044G15 product:weakly similar to GLYCOGEN PHOSPHORYLASE (EC 2.4.1.1) (ALPHA-GLUCAN PHOSPHORYLASE) (STARCH PHOSPHORYLASE) [Mus musculus], full insert sequence [ |
KLA | .85 |
.87 |
.84 |
.91 |
.88 |
.84 |
.95 |
| ATP | 1.04 |
1.03 |
.99 |
1.07 |
.95 |
.80 |
.83 |
| KLA/ATP | .88 |
.88 |
.95 |
.97 |
.98 |
.87 |
.76 |
|
Pygl | |
NM_133198 |
liver glycogen phosphorylase (Pygl), mRNA [NM_133198] |
KLA | .79 |
.76 |
.73 |
.67 |
.52 |
.42 |
.66 |
| ATP | 1.01 |
.94 |
1.24 |
1.10 |
.92 |
.55 |
.44 |
| KLA/ATP | .76 |
.81 |
.93 |
.81 |
.76 |
.45 |
.14 |
|
Pygm | |
NM_011224 |
muscle glycogen phosphorylase (Pygm), mRNA [NM_011224] |
KLA | 1.11 |
1.08 |
.97 |
1.00 |
1.09 |
1.13 |
1.19 |
| ATP | 1.02 |
.98 |
.97 |
2.09 |
1.91 |
1.71 |
1.11 |
| KLA/ATP | 1.15 |
1.06 |
.87 |
1.65 |
1.87 |
1.99 |
1.42 |
|
RP23-136 K12.4 | |
NM_008916 |
putative phosphatase (Pps), mRNA [NM_008916] |
KLA | 1.35 |
1.47 |
1.81 |
1.90 |
2.21 |
2.28 |
1.37 |
| ATP | 1.00 |
1.04 |
1.03 |
1.11 |
.86 |
.77 |
1.25 |
| KLA/ATP | 1.45 |
1.56 |
1.59 |
1.74 |
1.57 |
1.45 |
2.55 |
|
Raf1 | |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 | |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Rapgef1 | |
NM_001039087 |
Rap guanine nucleotide exchange factor (GEF) 1 (Rapgef1), transcript variant 1, mRNA [NM_001039087] |
KLA | .93 |
.89 |
.88 |
.67 |
.73 |
.90 |
1.16 |
| ATP | 1.12 |
1.09 |
.82 |
1.25 |
1.43 |
1.63 |
1.58 |
| KLA/ATP | 1.03 |
.95 |
.67 |
.74 |
.65 |
.89 |
1.77 |
|
Rheb | |
NM_053075 |
RAS-homolog enriched in brain (Rheb), mRNA [NM_053075] |
KLA | 1.03 |
1.00 |
.99 |
.99 |
.95 |
1.03 |
1.09 |
| ATP | .99 |
.89 |
.95 |
.81 |
1.07 |
1.19 |
.90 |
| KLA/ATP | 1.01 |
.87 |
.97 |
.82 |
1.06 |
1.22 |
.88 |
|
Rhoq | |
NM_145491 |
ras homolog gene family, member Q (Rhoq), mRNA [NM_145491] |
KLA | .88 |
.85 |
1.14 |
1.67 |
2.93 |
2.44 |
2.37 |
| ATP | .96 |
.88 |
.93 |
.71 |
.86 |
.69 |
.85 |
| KLA/ATP | .83 |
.77 |
.83 |
.70 |
1.10 |
.54 |
.66 |
|
Rps6 | |
AK013825 |
adult male hippocampus cDNA, RIKEN full-length enriched library, clone:2900086I01 product:ribosomal protein S6, full insert sequence. [AK013825] |
KLA | 1.04 |
1.06 |
1.03 |
.99 |
.94 |
.96 |
1.26 |
| ATP | 1.01 |
1.00 |
1.04 |
.99 |
.99 |
.94 |
1.12 |
| KLA/ATP | 1.02 |
1.08 |
.95 |
1.04 |
.94 |
.97 |
.90 |
|
Rps6 | |
NM_009096 |
ribosomal protein S6 (Rps6), mRNA [NM_009096] |
KLA | 1.01 |
1.01 |
.94 |
.87 |
.89 |
.66 |
.72 |
| ATP | 1.11 |
1.07 |
1.10 |
1.12 |
1.12 |
1.03 |
.47 |
| KLA/ATP | .96 |
1.04 |
1.22 |
1.10 |
.86 |
.84 |
.40 |
|
Rps6kb1 | |
NM_001114334 |
ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 1, mRNA [NM_001114334] |
KLA | .99 |
1.00 |
.90 |
.89 |
.99 |
.99 |
.92 |
| ATP | 1.01 |
.96 |
1.00 |
.79 |
1.36 |
1.19 |
.72 |
| KLA/ATP | 1.08 |
.99 |
.93 |
.92 |
1.18 |
.90 |
.56 |
|
Rps6kb1 | |
NM_028259 |
ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 2, mRNA [NM_028259] |
KLA | 1.01 |
.93 |
1.07 |
1.04 |
.99 |
.99 |
.98 |
| ATP | 1.09 |
1.05 |
1.00 |
1.01 |
1.08 |
1.03 |
1.03 |
| KLA/ATP | 1.07 |
1.04 |
.94 |
.98 |
1.03 |
1.05 |
1.05 |
|
Rps6kb2 | |
AK090093 |
kidney CCL-142 RAG cDNA, RIKEN full-length enriched library, clone:G430107K15 product:ribosomal protein S6 kinase, 70kD, polypeptide 2, full insert sequence [AK090093] |
KLA | .97 |
1.01 |
.98 |
.97 |
.98 |
1.04 |
1.07 |
| ATP | 1.00 |
1.08 |
1.06 |
1.09 |
1.11 |
1.06 |
1.03 |
| KLA/ATP | 1.05 |
.96 |
.86 |
1.03 |
1.40 |
1.07 |
.99 |
|
Rps6kb2 | |
NM_021485 |
ribosomal protein S6 kinase, polypeptide 2 (Rps6kb2), mRNA [NM_021485] |
KLA | 1.36 |
1.40 |
1.45 |
1.40 |
1.63 |
1.57 |
1.46 |
| ATP | 1.08 |
1.19 |
.97 |
1.15 |
.90 |
.99 |
1.34 |
| KLA/ATP | 1.44 |
1.55 |
1.09 |
1.39 |
1.00 |
1.12 |
1.77 |
|
Sh2b2 | |
NM_018825 |
SH2B adaptor protein 2 (Sh2b2), mRNA [NM_018825] |
KLA | .89 |
.94 |
.95 |
1.10 |
1.67 |
1.80 |
1.78 |
| ATP | 1.03 |
1.15 |
1.05 |
1.62 |
4.24 |
2.85 |
1.90 |
| KLA/ATP | 1.03 |
.97 |
.88 |
1.41 |
2.83 |
3.50 |
3.87 |
|
Shc1 | |
NM_011368 |
src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] |
KLA | .88 |
.87 |
.86 |
.83 |
1.09 |
1.11 |
1.12 |
| ATP | 1.04 |
1.25 |
.85 |
1.17 |
.93 |
1.16 |
1.00 |
| KLA/ATP | .93 |
.96 |
.62 |
.96 |
.75 |
1.25 |
1.19 |
|
Shc2 | |
NM_001024539 |
src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] |
KLA | 1.19 |
1.25 |
1.22 |
1.16 |
1.15 |
1.14 |
.98 |
| ATP | 1.04 |
1.14 |
1.15 |
1.53 |
1.29 |
1.06 |
1.09 |
| KLA/ATP | 1.26 |
1.24 |
1.26 |
1.49 |
1.31 |
1.30 |
1.30 |
|
Shc3 | |
NM_009167 |
src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] |
KLA | 1.00 |
.98 |
1.06 |
1.06 |
1.12 |
1.08 |
1.04 |
| ATP | .99 |
1.02 |
1.00 |
1.05 |
1.00 |
1.08 |
1.08 |
| KLA/ATP | 1.08 |
1.06 |
1.01 |
1.06 |
1.03 |
1.12 |
1.41 |
|
Shc4 | |
NM_199022 |
SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] |
KLA | 1.03 |
1.03 |
1.01 |
1.06 |
1.09 |
1.03 |
1.06 |
| ATP | .99 |
1.00 |
1.03 |
1.02 |
1.04 |
1.04 |
1.01 |
| KLA/ATP | .98 |
.97 |
1.06 |
1.05 |
1.00 |
1.00 |
1.14 |
|
Slc2a4 | |
NM_009204 |
solute carrier family 2 (facilitated glucose transporter), member 4 (Slc2a4), mRNA [NM_009204] |
KLA | 1.08 |
1.10 |
1.09 |
1.10 |
1.08 |
1.01 |
.98 |
| ATP | 1.02 |
.98 |
1.01 |
1.02 |
.98 |
.96 |
1.00 |
| KLA/ATP | 1.07 |
1.08 |
1.07 |
1.06 |
1.03 |
1.01 |
.99 |
|
Socs1 | |
NM_009896 |
suppressor of cytokine signaling 1 (Socs1), mRNA [NM_009896] |
KLA | 27.36 |
22.16 |
20.64 |
23.08 |
17.74 |
21.71 |
10.12 |
| ATP | .91 |
.72 |
2.03 |
12.69 |
9.16 |
19.87 |
6.80 |
| KLA/ATP | 26.70 |
24.56 |
28.15 |
31.28 |
26.32 |
29.95 |
22.51 |
|
Socs2 | |
AK033206 |
15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030460M17 product:hypothetical SH2 motif [AK033206] |
KLA | 1.08 |
1.11 |
1.22 |
1.13 |
1.11 |
1.08 |
.97 |
| ATP | .98 |
.97 |
1.03 |
1.03 |
1.29 |
1.30 |
1.29 |
| KLA/ATP | 1.06 |
1.09 |
1.07 |
1.33 |
2.01 |
1.85 |
1.98 |
|
Socs2 | |
NM_007706 |
suppressor of cytokine signaling 2 (Socs2), mRNA [NM_007706] |
KLA | 2.03 |
2.28 |
2.61 |
1.98 |
1.59 |
1.72 |
1.28 |
| ATP | 1.04 |
1.04 |
1.05 |
1.17 |
2.11 |
3.47 |
3.02 |
| KLA/ATP | 2.18 |
1.92 |
1.71 |
2.33 |
3.37 |
5.81 |
4.64 |
|
Socs3 | |
NM_007707 |
suppressor of cytokine signaling 3 (Socs3), mRNA [NM_007707] |
KLA | 7.56 |
6.68 |
6.29 |
7.36 |
6.47 |
7.03 |
5.33 |
| ATP | 1.51 |
1.75 |
4.63 |
6.27 |
6.92 |
7.74 |
4.64 |
| KLA/ATP | 6.82 |
6.77 |
9.19 |
8.32 |
9.51 |
8.98 |
8.33 |
|
Socs4 | |
AK080408 |
7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730004F22 product:unclassifiable, full insert sequence [AK080408] |
KLA | .89 |
.90 |
.87 |
.74 |
.87 |
1.05 |
.98 |
| ATP | 1.01 |
.97 |
1.11 |
.76 |
1.00 |
.82 |
1.11 |
| KLA/ATP | .80 |
.82 |
.82 |
.70 |
1.00 |
.80 |
.76 |
|
Socs4 | |
NM_080843 |
suppressor of cytokine signaling 4 (Socs4), mRNA [NM_080843] |
KLA | 1.31 |
1.29 |
1.45 |
1.31 |
1.42 |
1.90 |
2.37 |
| ATP | 1.02 |
1.16 |
1.31 |
1.39 |
1.86 |
2.43 |
2.69 |
| KLA/ATP | 1.33 |
1.24 |
1.26 |
1.31 |
1.39 |
2.94 |
3.73 |
|
Sorbs1 | |
NM_178362 |
sorbin and SH3 domain containing 1 (Sorbs1), transcript variant 2, mRNA [NM_178362] |
KLA | .92 |
.85 |
.90 |
.76 |
.93 |
.86 |
.86 |
| ATP | .96 |
1.02 |
.95 |
.73 |
.70 |
1.05 |
.79 |
| KLA/ATP | .86 |
.85 |
.93 |
.70 |
.74 |
1.25 |
1.40 |
|
Sos1 | |
NM_009231 |
Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] |
KLA | 2.36 |
2.40 |
3.42 |
3.15 |
2.78 |
1.81 |
1.71 |
| ATP | .99 |
1.00 |
.99 |
1.15 |
1.14 |
1.25 |
1.24 |
| KLA/ATP | 2.41 |
2.26 |
1.95 |
2.44 |
1.47 |
1.66 |
1.37 |
|
Sos2 | |
XM_127051 |
gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] |
KLA | .81 |
.77 |
.79 |
.92 |
1.04 |
1.06 |
1.20 |
| ATP | 1.00 |
1.00 |
1.09 |
.79 |
.68 |
.81 |
.94 |
| KLA/ATP | .77 |
.69 |
.71 |
.60 |
.64 |
.77 |
1.07 |
|
Srebf1 | |
NM_011480 |
sterol regulatory element binding transcription factor 1 (Srebf1), mRNA [NM_011480] |
KLA | .58 |
.53 |
.54 |
.53 |
.62 |
.65 |
.84 |
| ATP | .99 |
1.04 |
.99 |
1.00 |
.78 |
.75 |
.88 |
| KLA/ATP | .58 |
.53 |
.52 |
.52 |
.47 |
.50 |
.49 |
|
Trip10 | |
NM_134125 |
thyroid hormone receptor interactor 10 (Trip10), mRNA [NM_134125] |
KLA | 3.41 |
3.14 |
3.00 |
1.86 |
1.18 |
.99 |
1.12 |
| ATP | 1.06 |
1.09 |
1.01 |
1.48 |
2.79 |
1.67 |
.90 |
| KLA/ATP | 3.71 |
3.95 |
2.99 |
3.72 |
2.94 |
1.46 |
.93 |
|
Tsc1 | |
AK083363 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:C920023H23 product:tuberous sclerosis 1, full insert sequence. [AK083363] |
KLA | .69 |
.66 |
.60 |
.71 |
.85 |
.78 |
.77 |
| ATP | 1.13 |
1.26 |
1.70 |
2.23 |
1.77 |
.87 |
.90 |
| KLA/ATP | .76 |
.77 |
.90 |
1.19 |
1.74 |
.80 |
.72 |
|
Tsc1 | |
NM_022887 |
tuberous sclerosis 1 (Tsc1), mRNA [NM_022887] |
KLA | .93 |
.94 |
1.00 |
1.04 |
1.01 |
.95 |
1.10 |
| ATP | 1.12 |
1.10 |
1.12 |
1.27 |
1.66 |
1.45 |
1.80 |
| KLA/ATP | .95 |
1.00 |
1.06 |
1.03 |
1.26 |
1.30 |
1.74 |
|
Tsc2 | |
NM_011647 |
tuberous sclerosis 2 (Tsc2), transcript variant 1, mRNA [NM_011647] |
KLA | .91 |
.88 |
.87 |
.83 |
.83 |
.88 |
.99 |
| ATP | .91 |
.91 |
1.04 |
.88 |
.76 |
.68 |
.91 |
| KLA/ATP | .88 |
.89 |
.88 |
.76 |
.65 |
.67 |
.85 |
|